Current recommendations for the treatment of hypertension clarify the need to achieve lower blood pressure levels in the general population (<140/90 mm Hg) and in specific high-risk patient groups such as patients with diabetes or chronic renal disease (<130/80 mm Hg
T he majority of evidence demonstrating that lowering blood pressure reduces the risk of cardiovascular disease (CVD) events is derived from clinical trials of diureticbased or β blocker-based therapies, 1 and clinical recommendations endorsed these two classes of agents as initial treatment for hypertension. 2, 3 The most current recommendations now suggest that blood pressure levels recently labeled "normal" may represent "prehypertension" due to their association with increased CVD risk. 4 After early trials with diuretics and β blockers established that lowering elevated blood pressure improved outcomes, researchers set out to determine if other antihypertensive therapies might reduce events still further. 5 Before 1999, no published mortality/morbidity trial had compared the effects of newer antihypertensive medications (such as angiotensinconverting enzyme [ACE] inhibitors, calcium channel blockers [CCBs] , and α blockers) with diuretics and β blockers in the treatment of essential hypertension. 6 In the past 10 years, ACE inhibitors and CCBs have demonstrated efficacy at reducing CVD morbidity and mortality compared with placebo in a wide range of high-risk patient groups. 4 In comparative trials with these agents and diuretic/β blockers, equivalent reductions in cardiovascular events have been noted. 5 The antihypertensive class of angiotensin II receptor blockers (ARBs) has demonstrated the ability to lower blood pressure, and clinical trial data demonstrating the cardioprotective effects of ARBs are emerging. The recent Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) 7 trial was the first large study to actually show superiority in primary clinical outcomes (primarily strokes) for a newer agent, the ARB losartan, compared with an older agent, the β blocker atenolol (Figure 1) .
Despite an enormous amount of accumulated trial data, there is still debate about which agent as monotherapy, or which combination regimen, is superior in reducing overall CVD morbidity and mortality or total mortality. This lack of evidence does not prove or disprove superiority of some classes compared to others; instead, it reflects limitations in the trial designs, 6-14 which prevent the detection of differences that may exist. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) 8 is an important case in point. This large study, sponsored by the National Heart, Lung and Blood Institute, showed no difference among three major antihypertensive classes (diuretics, ACE inhibitors, and CCBs) for the primary clinical outcome. However, there were fewer episodes of congestive heart failure in the diuretic compared with the amlodipine group and fewer strokes and congestive heart failure cases compared with patients on lisinopril. However, less than 50% of patients in the ALLHAT trial achieved blood pressure control on monotherapy. Thus, the ALLHAT trial investigated a strategy of controlling blood pressure with a regimen that began with a diuretic, an ACE inhibitor, or a CCB but in most cases required add-on therapy. The superiority of any specific monotherapy may have been obscured. Moreover, the study design forced together combinations that clinicians seldom choose. As in recent clinical trials, the need for combination therapy to achieve blood pressure control has hampered investigators in their efforts to delineate clear differences among classes of agents.
A clear message has emerged from the era of clinical trials that attempted to determine the superiority of specific drug classes: Lowering blood pressure imparts cardioprotection; the specific agent used to achieve control may have less importance. Frequently, multiple drug classes are needed to achieve control. The recently published seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) 4 suggests that patients with a systolic blood pressure 20 mm Hg or more above goal receive combination therapy (rather than monotherapy) as the initial strategy for controlling blood pressure. Moreover, JNC 7 recommends a diuretic as part of the combination strategy. While this makes empirical sense, there are no clinical trial data demonstrating the clinical efficacy of initial combination therapy, nor is there much evidence to support any particular combination of drug classes. It appears that a new paradigm is needed for designing hypertension trials in the 21st century. This article describes the Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial, 15 the first large, randomized clinical trial to directly compare CVD mortality and morbidity rates for two preselected combination therapies.
THE NEW ERA: COMBINATION THERAPY
Most patients with hypertension require combination antihypertensive therapy, making this a better strategy for controlling blood pressure compared with monotherapy. Even high-dose monotherapy is generally less successful than low doses of agents from two separate classes for blood pressure control and tolerability. 16 It is possible that specific combinations of agents could improve CVD outcomes by targeting more than a single pathway in the pathology of hypertension. This benefit, if proven, would be of particular relevance in the treatment of high-risk patients. However, combination therapy has not previously been evaluated in a randomized clinical trial as a strategy for achieving blood pressure control and preventing CVD events in high-risk patients.
The ACCOMPLISH study 15 is a large outcomes trial that will randomize subjects to a specific fixed-dose combination agent as initial therapy. This ongoing trial will evaluate whether the fixed-dose combination of an ACE inhibitor/CCB (amlodipine besylate/benazepril HCl) provides superior benefits in reducing morbidity and mortality from CVD events in a high-risk hypertensive population when compared with an ACE inhibitor/diuretic combination (benazepril HCl/hydrochlorothiazide).
The Role for ACE Inhibitors in
High-Risk Patients ACE inhibitors will be included in the regimens of both groups of participants in ACCOMPLISH because of their proven benefits in a wide range of high-risk patients. The class of ACE inhibitors has been used for lowering blood pressure for more than 20 years and has been shown to be beneficial in elderly individuals 17 and in patients with heart failure, myocardial infarction (MI), diabetes, diabetic and nondiabetic chronic renal disease, and atherosclerotic vascular disease. 4,18-22 ACE inhibitors have demonstrated the ability to reduce the incidence of cardiac death, nonfatal MI, stroke, end-stage renal disease, and complications of heart failure. 4,18,22 They have also been shown to improve insulin resistance in patients with metabolic syndrome; reduce CVD events in patients with diabetes 23 ; and have a beneficial effect on the microvasculature of the kidney in patients with diabetes. 24 In the African American Study of Kidney Disease and Hypertension (AASK), 18 conducted in 1094 African Americans with hypertension and nondiabetic chronic renal insufficiency, an antihypertensive regimen based on the ACE inhibitor ramipril was superior to regimens based on the β blocker atenolol or the CCB amlodipine besylate for the combined clinical outcome of reduction in glomerular filtration rate by ≥50% from baseline, development of end-stage renal disease, or death. The AASK trial was the first outcome trial to demonstrate a renoprotective effect of ACE inhibitors in African Americans. Through the Heart Outcomes Prevention Evaluation (HOPE) 25 study, the benefits of ACE inhibitors have been extended to a wide range of high-risk patients, including those without elevated blood pressure. It is important to note that all of the above studies were multiple drug studies; a majority of patients received medications (usually a diuretic) in addition to the ACE inhibitor to achieve goal blood pressures.
Beyond their ability to reduce blood pressure, the beneficial effects of ACE inhibitors are due to their mechanism of action. ACE inhibition opposes the multiple pathologies that are involved in morbidities that are collectively attributable to activation of the renin-angiotensin-aldosterone system and subsequent increased production of angiotensin II. Angiotensin II promotes vasoconstriction, abnormal smooth muscle cell migration, macrophage activation, and platelet aggregation, and contributes to cardiac and vascular hypertrophy, endothelial dysfunction, and altered renal hemodynamics. Both experimental and clinical evidence suggests that ACE inhibition has beneficial effects by inhibiting vasoconstriction, endothelial dysfunction, the development of atherosclerosis, and thrombus formation. 20, [26] [27] [28] [29] [30] [31] 
CCBs vs. Diuretics in High-Risk Patients
Because both groups in ACCOMPLISH will receive the ACE inhibitor benazepril HCl, the study is designed to specifically differentiate the combination of an ACE inhibitor/CCB vs. an ACE inhibitor/diuretic. Based on currently available data, neither diuretics nor CCBs can claim to be 40 superior in combination with an ACE inhibitor. Although ALLHAT 8 data suggest that a diuretic is unsurpassed as an initial therapy for hypertension, with fewer episodes of heart failure than a CCB, the trial provided little clarification regarding optimal regimens for combination therapy; even though, on average, ALLHAT participants took two agents, and blood pressure levels <140/90 mm Hg were achieved in >60% of patients. The combinations being studied in ACCOMPLISH were not utilized in the protocol for ALLHAT.
In an overview of randomized controlled clinical trials 5 comparing CCBs with other diuretics or β blockers, there was no clear winner. Outcomes for stroke were somewhat better with CCB treatment; outcomes for coronary heart disease and heart failure were somewhat better with diuretics; and neither was superior for major CVD events, CVD death, or total mortality. A meta-analysis 32 of trials including more than 46,000 patients showed similar findings: CCBs demonstrated a lower risk of nonfatal stroke (−25%; p=0.004) and a higher risk of total MI (18%; p=0.052) compared with diuretics or β blockers; thus, stroke reduction more than balanced increased MI, although MIs are a more frequent event (Figure 2) . Some data suggest a potential role for CCBs-and amlodipine besylate in particular-in the prevention or regression of atherosclerosis. 33, 34 In the Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT), 35 treatment with amlodipine besylate produced benefits compared with placebo, demonstrating marked reductions in CVD events as well as reductions in the progression of carotid atherosclerosis. Further, amlodipine besylate has been shown to have a favorable effect on morbidity and mortality in patients with nonischemic heart failure. 36 Data from experimental studies support the hypothesis that some of the beneficial effects of ACE inhibitors in the treatment of heart failure may be due to the release of nitric oxide secondary to local generation of kinins. 37, 38 In animal studies, amlodipine besylate-but not nifedipine or diltiazem-was found to cause a significant, dose-dependent increase in nitrite (the hydration product of nitric oxide) production that was similar in magnitude to that found with ACE inhibitors. 39 Further, in combination, amlodipine besylate potentiated nitrite production produced by ramiprilat-the active metabolite of the ACE inhibitor ramipril 40 (Figure 3) .
ACCOMPLISH
The ACCOMPLISH trial will compare amlodipine besylate/benazepril HCl and benazepril HCl/hydrochlorothiazide for the clinical outcomes of CVD morbidity and mortality in high-risk hypertensive individuals. It is planned that this prospective, randomized, double-blind trial will enroll 12,600 patients at approximately 650 multinational centers. The duration of this event-driven trial is expected to be about 5 years. The blood pressure target will be <140/90 mm Hg, but a more aggressive target (i.e., <130/80 mm Hg) for patients with diabetes or renal disease may be utilized at the discretion of the individual investigator.
The trial's primary end point is a composite of CVD death, nonfatal MI, nonfatal stroke, hospitalization for unstable angina, or revascularization procedure. Secondary end points will include individual end points within the primary end point, allcause mortality, hospitalization for heart failure, progression of renal disease, and development of diabetes.
SUMMARY
Combination therapy is currently the mainstay of treatment for hypertension; however, controlled clinical trials have previously only studied monotherapy or single-agent-based therapy with the use of open-label, add-on agents to achieve blood pressure control. Despite the large amount of data amassed, only a single trial based on this design paradigm has found one class of agents (ARBs) to be superior to another (β blockers) in reducing CVD events. There is little evidence available from completed trials to guide clinicians in the selection of combination antihypertensive regimens for high-risk patients. It is time to look at a new paradigm in hypertension trials. The ACCOM-PLISH trial is the first large, randomized hypertension clinical trial to compare CVD mortality and morbidity in high-risk hypertensive patients with two different combination regimens: amlodipine besylate/benazepril HCl vs. benazepril HCl/hydrochlorothiazide.
